Vikram Pattanayak, MD, PhD
Vikram Pattanayak, MD, PhD
Instructor in Pathology, Harvard Medical School
About Vikram Pattanayak, MD, PhD
Vikram Pattanayak is an Assistant in Pathology at Massachusetts General Hospital and an Instructor in Pathology at Harvard Medical School. He has completed a residency in clinical pathology and fellowship in molecular genetic pathology and serves as the director of the Massachusetts General Hospital histocompatibility (HLA) laboratory.
In addition to his clinical interests, Dr. Pattanayak leads a subgroup of Keith Joung’s laboratory focused on the development of genome editing tools. During his M.D., Ph.D. thesis work with David Liu in the Harvard Chemistry department, he developed assays to define the specificities of designer endonucleases, including homing endonucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and Cas9. As a member of the Joung lab, he engineered a variant of Cas9 (SpCas9-HF1) with minimal off-target effects.
Clinical Interests:
- Clinical Pathology
- Coagulation
Treats:
- Adult
Locations
Pathology Associates
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-643-0082
Medical Education
- M.D.; Ph.D., Harvard Medical School
- MD, Harvard Medical School/ BWH
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital
American Board Certifications
- Clinical Pathology, American Board of Pathology
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- MassHealth
- Medicare
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Publications
-
View my most recent publications at PubMed
Lareau, C.A., Clement, K., Hsu, J.Y., Pattanayak, V., Joung, J.K., Aryee, M.J., Pinello, L. Response to “Unexpected mutations after CRISPR-Cas9 editing in vivo.” Nature Methods. 15: 238, 2018.
Kleinstiver, B.P.*, Pattanayak, V.*, Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z., Joung, J.K. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 529: 490, 2016.
Pattanayak, V.*, Guilinger, J.P.*, Liu, D.R. Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. Methods in Enzymology. 546: 47, 2014.
Guilinger, J.P., Pattanayak, V., Reyon, D., Tsai, S.Q., Sander, J.D., Joung, J.K., Liu, D.R. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nature Methods. 11: 429, 2014.
Pattanayak, V., Lin, S., Guilinger, J.P., Ma, E., Doudna, J.A., Liu, D.R. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nature Biotechnology. 31: 839-843, 2013.
Pattanayak, V., Ramirez, C.L., Joung, J.K., Liu, D.R. Revealing off-target cleavage specificities of zinc finger nucleases by in vitro selection. Nature Methods. 9: 765-770, 2011.
Doyon, J.B., Pattanayak, V., Meyer, C.B., Liu, D.R. Directed evolution and substrate specificity profile of homing endonuclease I-SceI. J. Am. Chem. Soc. 128: 2477-84, 2006.